Why the study?
The 2020 ESC guidelines do not recommend P2Y12 inhibitor pretreatment in NSTEMI patients with unclear coronary anatomy, conflicting with routine preoperative loading practices.
Does P2Y12 inhibitor pretreatment reduce mortality or increase bleeding in patients with non-ST-segment elevation acute coronary syndrome compared to administration during or after PCI?
Does P2Y12 inhibitor pretreatment reduce mortality or increase bleeding in patients with non-ST-segment elevation acute coronary syndrome compared to administration during or after PCI?
Clopidogrel pretreatment in NSTE-ACS is associated with lower mortality and ischemic events without increased bleeding, whereas prasugrel or ticagrelor pretreatment increases bleeding without mortality benefit.
Answers are grounded in this paper and cite their sources.
Clopidogrel pretreatment may lower mortality without excess bleeding in NSTE-ACS; supports selective use while challenging prasugrel/ticagrelor pretreatment.
BACKGROUND: The 2020 European Society of Cardiology guidelines do not recommend pretreatment for nonST-segment elevation myocardial infarction (NSTEMI) patients with unclear coronary anatomy, which is inconsistent with our routine preoperative approach to loading P2Y12 receptor inhibitors (e.g., preoperative loading of 300 mg of clopidogrel). OBJECTIVES: The purpose of our study was to compare the safety and effectiveness of P2Y12 inhibitors administered before coronary angiography or at least before percutaneous coronary intervention (PCI) with during or after PCI. METHODS: Cochrane, PubMed, and Embase databases were searched. The primary effect endpoint and safety endpoint were any-cause death and major bleeding, respectively. Major adverse cardiovascular events, myocardial infarction and revascularization were also analyzed. RESULTS: Our search identified 9 trials. P2Y12 inhibitor pretreatment was associated with lower death from any cause (OR 0.62, 95% CI 0.53-0.72, P < 0.00001) without increasing the risk of bleeding (OR 1.02, 95% CI 0.80-1.30, P = 0.89). However, prasugrel or ticagrelor pretreatment was not associated with a lower risk of mortality (OR 0.70, 95% CI 0.31-1.59, P = 0.40) and increased the risk of bleeding (OR 1.67, 95% CI 1.10-2.54, P = 0.02). CONCLUSIONS: In summary, clopidogrel pretreatment was associated with significantly lower mortality, major adverse cardiovascular events, myocardial infarction and revascularization with no increase in major bleeding. However, these advantages were not observed with prasugrel or ticagrelor pretreatment.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: